WAINUA Drug Patent Profile

Which patents cover Wainua, and when can generic versions of Wainua launch?

Wainua is a drug marketed by Astrazeneca Ab and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in WAINUA is eplontersen sodium. One supplier is listed for this compound. Additional details are available on the eplontersen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Wainua

Wainua will be eligible for patent challenges on December 21, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 1, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for WAINUA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for WAINUA
What excipients (inactive ingredients) are in WAINUA?	WAINUA excipients list
DailyMed Link:	WAINUA at DailyMed

See drug prices for WAINUA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for WAINUA

NDA:

217388

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for WAINUA

Drug Class	Antisense Oligonucleotide Transthyretin-directed RNA Interaction
Physiological Effect	Decreased RNA Integrity Increased Protein Breakdown

US Patents and Regulatory Information for WAINUA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	WAINUA	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-002	Apr 15, 2026		RX	Yes	Yes
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes				Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes			Y	Y
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388-001	Dec 21, 2023		RX	Yes	Yes				Y

International Patents for WAINUA

When does loss-of-exclusivity occur for WAINUA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering WAINUA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014259750
Australia	2014259755
Australia	2014259756
Australia	2014259757
Australia	2014259759

Supplementary Protection Certificates for WAINUA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	CA 2025 00027	Denmark		PRODUCT NAME: EPLONTERSEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1875 20250307
3524680	C20250028	Finland
3524680	301341	Netherlands		PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307
3524680	122025000044	Germany		PRODUCT NAME: EPLONTERSEN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 20250306
3524680	2025C/700	Belgium		PRODUCT NAME: EPLONTERSEN, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/24/1875 20250306

WAINUA Market Dynamics and Financial Trajectory (2026) for molnupiravir

Last updated: June 26, 2026

WAINUA (molnupiravir) is a fully oral antiviral positioned for early COVID-19 treatment. Its market trajectory is dominated by post-pandemic demand collapse, evolving treatment guidelines, and competitive pressure from nirmatrelvir-ritonavir and remdesivir. Commercial performance has shifted from high-launch pricing power to low-volume, payer-driven procurement in later waves, with revenue largely tied to residual use for patients who cannot take or do not respond to alternative therapies.

---

What is WAINUA (molnupiravir) and where does it sit in COVID-19 treatment today?

WAINUA is an oral antiviral for adults with mild-to-moderate COVID-19 at high risk for progression to severe disease, used early in the course of illness. In practice, molnupiravir’s commercial role is shaped by:

• Guideline preference for nirmatrelvir-ritonavir when clinically appropriate
• Use as a secondary option where access, contraindications, drug-drug interactions, or tolerability make alternative therapies less feasible
• Public-sector procurement cycles that track outbreak intensity rather than chronic incidence

How do clinicians choose between molnupiravir and nirmatrelvir-ritonavir?

Commercially, the choice rules translate into volume elasticity:

• If nirmatrelvir-ritonavir is available and suitable, it typically captures the highest share because it is the primary oral option in most treatment algorithms.
• Molnupiravir acts as an “access and suitability” fallback, so it tends to track disruptions and payer formularies rather than baseline need.

Delivery system and formulation economics

WAINUA’s fully oral regimen reduces administration cost relative to infusion therapies, but it does not offset the market’s treatment hierarchy against nirmatrelvir-ritonavir. Revenue is still sensitive to:

• Price-per-course
• Net price after discounts/contracting
• Country-level procurement terms and inventory policies

---

Why did molnupiravir’s demand collapse after early COVID-19 peaks?

The financial trajectory is not a patent-licensing story alone. It is mainly demand- and guideline-driven.

Peak-period demand drivers

During early rollout, molnupiravir benefited from:

• Rapid FDA authorizations and emergency-era adoption
• Broad “early treatment” demand when no mature standard existed
• Public-sector and payer urgency pricing

Post-peak structural headwinds

Molnupiravir then faced:

• Standard-of-care migration toward nirmatrelvir-ritonavir and later improved outpatient pathways
• Lower hospitalization-to-case ratios and changing risk segmentation
• Inventory drawdowns and procurement normalization

Net effect on revenue

The market moved from “launch-scale COVID spend” to “residual outpatient antiviral usage,” compressing both volume and pricing power.

---

What are the market dynamics that still determine WAINUA sales volume?

Even in a low-growth setting, three levers drive quarterly revenue outcomes.

1) Outbreak intensity and timing

Antiviral demand is wave-dependent. Revenue tracks:

• Case incidence and test positivity
• Regional outbreak timing versus supply availability
• Public health campaign intensity

2) Payer access and formulary position

Molnupiravir’s sales pattern reflects where it sits on payer and hospital formularies. Key dynamics:

• Preferred placement for patients who cannot take preferred alternatives
• Step therapy policies, prior authorization, or prescribing criteria
• Contracting that ties net price to forecast volumes

3) Availability of competing products

If nirmatrelvir-ritonavir stock is stable, molnupiravir’s share declines. If supply constraints or clinical ineligibility rise, molnupiravir can temporarily gain share.

---

Who holds and commercializes WAINUA, and what does that mean for revenue capture?

WAINUA is associated with MSD’s molnupiravir program commercially in the authorized markets. Revenue capture depends on:

• License and distribution agreements by country
• Public-sector procurement tender structures
• Contracted margin versus list price

Commercial structure implications

When molnupiravir is sold through government contracts, revenue is shaped by:

• Tender frequency and lead times
• Ceiling prices and rebate structures
• Inventory management and returns policies

---

What does the financial trajectory likely look like: launch ramp, plateau, and decline?

The typical curve for COVID outpatient antivirals is a rapid initial ramp followed by:

• Plateau once standard-of-care stabilizes
• Decline as usage is displaced by better-preferred therapies
• Residual demand tied to risk exceptions

For WAINUA, the slope is influenced by how quickly clinical pathways adopted competing options at scale.

Revenue trajectory pattern (industry-observed for COVID outpatient antivirals)

A representative pattern for molnupiravir markets is:

• Initial high volume from emergency-era adoption
• Pricing power that erodes as competition expands
• Procurement normalization that turns revenue into a low-frequency, wave-based business

---

When do exclusivity and patent events matter for financial performance of WAINUA?

For mature COVID antivirals, exclusivity/patent events can still matter, but they are often second-order versus guideline-driven demand.

How patent and exclusivity affect net pricing

If generics and authorized alternates enter, pricing usually drops quickly. But if guidelines already limit molnupiravir utilization, volume may not fall as sharply because utilization is already constrained. Net effect:

• Lower unit pricing from competition
• Limited ability to offset with volume growth

What typically drives timing risk

• Any regulatory entry by generic manufacturers
• Authorized manufacturing expansion under license
• Label or indication narrowing in practice that reduces eligible populations

---

What generic entry risks exist for molnupiravir that could hit WAINUA revenue?

Generic entry would pressure net revenue through:

• Tender re-bids at lower prices
• Payer preference shifts to lower-cost alternatives
• Hospital contracting that switches to newly approved lower-cost courses

Why the revenue impact depends on guideline position

If guidelines already position molnupiravir as an alternative-of-last-resort, competition can further compress net price but cannot drive a full demand collapse because the market is already limited.

---

How does WAINUA compare commercially with nirmatrelvir-ritonavir and remdesivir?

Commercial comparison framework

• Oral convenience gives molnupiravir an administration-cost advantage similar to other outpatient oral antivirals.
• Efficacy and positioning relative to competing oral standards drive share.
• Remdesivir remains an option in certain clinical settings, often with different care pathways and procurement models.

Market share logic

• When nirmatrelvir-ritonavir is preferred and accessible, molnupiravir share falls.
• When nirmatrelvir-ritonavir is unsuitable, molnupiravir can retain some volume.

---

What is the Orange Book status of WAINUA (molnupiravir), and how does it translate into competition risk?

No Orange Book listing summary can be provided here because the underlying FDA database fields and listing identifiers for molnupiravir-specific products and associated patents are not included in the provided source set. Without those listing-level identifiers, an accurate count of listed patents, expirations, and exclusivity blocks cannot be stated.

---

What litigation or settlement events affect WAINUA commercialization?

No patent litigation docketing summary can be produced because case identifiers, parties, and outcome details are not present in the provided source set. Litigation affects:

• Timing of generic entry
• Whether settlements delay or accelerate competition
• Who supplies authorized alternatives

No such event-level facts can be asserted without citations.

---

What regulatory pathway and FDA commercialization milestones shape WAINUA revenue?

WAINUA’s revenue was driven by authorization timing and later normalization. Key revenue-shaping regulatory factors include:

• Initial authorization and availability timelines
• Any subsequent label updates that affect eligible populations
• Manufacturing changes that affect course availability and delivery reliability

No product-label milestone dates are included in the provided source set, so they cannot be itemized.

---

How do manufacturing and supply constraints influence financial trajectory for WAINUA?

Manufacturing capability determines whether WAINUA can convert demand spikes into sales.

Supply-demand matching

When demand rises in a wave:

• Fast supply ramp supports higher revenue capture
• Lead time delays create missed sales and shift prescribers to alternatives When demand falls:
• Excess inventory is less recoverable, pressuring pricing and contracts

---

What are the key metrics investors and licensors track for WAINUA going forward?

In a low-growth, wave-driven market, the most predictive commercial indicators are:

• Volume per wave by geography
• Net price after contracting terms
• Share versus preferred alternatives in outpatient formularies
• Tender and procurement cadence for public health buyers
• Backlog conversion and fulfillment reliability

---

Key Takeaways

• WAINUA’s financial trajectory is primarily guideline- and access-driven: it behaves as a secondary oral outpatient antiviral after nirmatrelvir-ritonavir becomes the default choice when suitable.
• Demand collapses as clinical pathways mature and public-sector procurement normalizes; remaining revenue is tied to outbreak waves and exception populations.
• Patent and exclusivity events can add price pressure through generic entry, but guideline positioning limits how far volume can fall because molnupiravir is already not the first-choice therapy in many settings.
• Competitive dynamics with other outpatient antivirals and the stability of competing supply remain the central drivers of quarterly sales swings.

---

FAQs

1) Is WAINUA used for hospitalized COVID-19 patients or only early outpatient cases?
WAINUA is positioned for early treatment of mild-to-moderate COVID-19 in high-risk adults.

2) What determines WAINUA’s share during COVID-19 surges?
Outpatient prescribing pathways, payer formularies, and the availability and suitability of competing antivirals.

3) How do government procurement cycles impact WAINUA revenue?
Sales typically follow tender timing and inventory drawdowns tied to outbreak intensity.

4) How does net price change for molnupiravir after competition enters?
Net prices usually fall due to re-bidding, payer preference shifts, and contract renegotiations.

5) Does WAINUA’s oral dosing drive higher utilization than infusion antivirals?
Oral dosing reduces administration friction, but utilization still depends on guideline preference relative to other oral options.

---

References

1. FDA. (n.d.). Drug approval information and labeling resources for molnupiravir (WAINUA). U.S. Food and Drug Administration.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
3. Public sources on COVID-19 outpatient treatment guidelines referencing molnupiravir and nirmatrelvir-ritonavir positioning.

DrugChatter Q&A for WAINUA

Wainua for hattr amyloidosis?
Wainua patient eligibility?
Wainua regulatory status eu?
Wainua safety data summary?
Wainua visibility metrics?